Full-Time
Confirmed live in the last 24 hours
Produces synthetic DNA for biotechnology applications
$110k - $130kAnnually
Mid, Senior
Remote in USA
Candidates must be based in NY, NJ, or PA.
You match the following Twist Bioscience's candidate preferences
Employers are more likely to interview you if you match these preferences:
Twist Bioscience creates synthetic DNA for use in biotechnology, pharmaceuticals, and research. Their proprietary platform allows for the quick and accurate production of DNA sequences, providing clients with products like genes, oligo pools, and variant libraries. They stand out by offering high-quality DNA at competitive prices and can handle complex sequences that many competitors cannot. The company's goal is to support advancements in personalized medicine and biotechnology through their innovative DNA synthesis solutions.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$236.5M
Headquarters
South San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Twist Bioscience named a Best Idea for 2025 at TD Cowen.
Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.
In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.
Twist Bioscience teams up with MedGenome to diagnose rare diseases.
Evolving Data StorageRecording data was crucial to civilization's founding. In fact, the invention of written records defined the separation between the prehistorical and historical periods. From early cuneiform clay tablets and papyrus scrolls to medieval books and the printing press, improvements in writing methods and technology have been transformative to human societies.Today, we record and handle more data than ever. But paradoxically, our storage mediums have become increasingly fragile. For example, we are now aware of disk rot, or CD rot, which is the degradation of the reflective layer of a compact disc (CD). It is likely that most of these storage devices, including museum archives, will be unreadable after mere decades. The same problem affects other optical storage methods like DVDs and Blu-rays.Similarly, hard drives can be very sensitive to electromagnetic waves, so most of the world's data could be erased by a sufficiently strong solar storm or EMP.So overall, compared to manuscripts written on vellum, papyrus, or clay, modern knowledge is just going to last a few decades or a century, or is one catastrophe away from total destruction.Luckily, researchers are exploring technologies for much more durable data storage. And amusingly enough, it might look a lot like the type of crystal we see in alien ships in science-fiction shows.Crystals’ DurabilityMost materials degrade in time, whether it be advanced engraving on silicon wafers or paper/animal skins
Twist Bioscience Corporation (NASDAQ:TWST), a company at the forefront of DNA synthesis technology, has recently announced its collaboration with bitBiome Inc. to release a new Transaminase Enzyme Screening Kit.
Twist Bioscience expands high-throughput IgG antibody portfolio with launch of CHO Express Antibodies.
Twist Bioscience launches synthetic RNA control for H5N1 Influenza A.